BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) [Trend Analysis] retains strong position in active trade, as shares scoring -1.42% to $6.25 in a active trade session, while looking at the shares volume, around 270829 shares have changed hands in this session. BioCrystPharma (BCRX) received approval for RAPIVAB in Canada. The firm reported that Health Canada has authorized RAPIVAB, an intravenous treatment for acute, uncomplicated influenza.RAPIVAB is authorized by the FDA and is also licensed for use in Japan and Taiwan as RAPIACTA and in Korea as PeramiFlu.RAPIVAB is being commercialized by Seqirus globally, excluding Japan, Taiwan, Korea and Israel. Seqirus is a leader in influenza prevention through the supply of seasonal and pandemic influenza vaccine to global markets. The firm has institutional ownership of 78.20%, while insider ownership included 1.60%. BCRX attains analyst recommendation of 2.60 with week’s performance of 0.16%. Investors looking further ahead will note that the Price to next year’s EPS is 8.80%.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) [Trend Analysis] knocking active thrust in leading trading session, shares a gain of 0.06% to 23.76 with around 19.21 Million shares have changed hands in this session. Takeda Pharmaceutical Company Limited (TKPYY.PK) and ARIAD Pharmaceuticals, Inc. (ARIA) reported a definitive contract under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or an enterprise value of approximately $5.2 billion.
Sarissa Capital, the holder of 6.6% of ARIAD’s common shares, as well as each of the members of ARIAD’s Board, have agreed to tender their shares to Takeda pursuant to the offer. The transaction will be funded by up to $4.0 billion of new debt and the remainder from existing cash. The transaction has no impact on Takeda’s dividend policy. Takeda Pharma said the acquisition of ARIAD brings two innovative targeted therapies that will enhance the company’s existing oncology portfolio.
Brigatinib, an investigational drug product, has the potential to add a differentiated, global therapy in a genetically-defined subpopulation of non-small cell lung cancer. The addition of Iclusig will broaden Takeda’s hematology franchise to include chronic myeloid leukemia and a subset of acute lymphoblastic leukemia. The stock is going forward its fifty-two week low with 443.82% and lagging behind from its 52-week high price with -0.19%.
Similar, the positive performance for the quarter recorded as 77.24% and for the year was 346.43%, while the YTD performance remained at 90.92%. ARIA has Average True Range for 14 days of 1.21.